Abstract
This review presents an overview of Choline Kinase (ChoK) inhibitors with antiproliferative activity. The consideration of ChoK as a novel target for the development of new anticancer drugs is justified. The synthesis of several derivatives based on structural modifications of hemicholinium-3 (HC-3) is not accompanied by potentiation of the neurological toxicity of HC-3. The increment of both ChoK inhibitory and antiproliferative activities was successfully obtained by the two following changes: a) substitution of the oxazonium moiety of HC-3 by several aromatic heterocycles, and b) using the 1,2-ethylene(bisbenzyl) moiety instead of the 4,4-biphenyl fragment. In an attempt to understand the ChoK inhibitory activity, a quantitative structure-activity relationship was developed. The QSAR equations have described the forces involved in quantitative terms. The electron characteristic of the substituent at position 4 of the heterocycle and the lipophilic character of the whole molecule were found to significantly affect the antitumour activity in compounds 17-95. Trispyridinium compounds 91-95 are more potent than the bispyridinium ones 87-89 as ChoK inhibitors. Nevertheless, 91-95 are less active than 87-89 as antiproliferative agents because the latter show better lipophilicities to cross the cytosolic membranes. Inhibition of the growth of human tumours in nude mice has been demonstrated: Antitumour activity of compound 64 against human HT-29 produced a decrease of up to 70% in the size of the tumour in nude mice. These results indicate that ChoK can be used as a general target for anticancer drug design against Ras-dependent tumourigenesis.
Keywords: choline kinase inhibitors, antitumour drugs, bisquaternary heterocyclic compounds, hammett parameters, lipophilicity, qsar, frontier orbitals
Current Medicinal Chemistry
Title: QSAR-Derived Choline Kinase Inhibitors: How Rational can Antiproliferative Drug Design Be?
Volume: 10 Issue: 13
Author(s): J. Campos, M. C. Nunez, A. Conejo-Garcia, R. M. Sanchez-Martin, R. Hernandez-Alcoceba, A. Rodriguez-Gonzalez, J. C. Lacal, M. A. Gallo and A. Espinosa
Affiliation:
Keywords: choline kinase inhibitors, antitumour drugs, bisquaternary heterocyclic compounds, hammett parameters, lipophilicity, qsar, frontier orbitals
Abstract: This review presents an overview of Choline Kinase (ChoK) inhibitors with antiproliferative activity. The consideration of ChoK as a novel target for the development of new anticancer drugs is justified. The synthesis of several derivatives based on structural modifications of hemicholinium-3 (HC-3) is not accompanied by potentiation of the neurological toxicity of HC-3. The increment of both ChoK inhibitory and antiproliferative activities was successfully obtained by the two following changes: a) substitution of the oxazonium moiety of HC-3 by several aromatic heterocycles, and b) using the 1,2-ethylene(bisbenzyl) moiety instead of the 4,4-biphenyl fragment. In an attempt to understand the ChoK inhibitory activity, a quantitative structure-activity relationship was developed. The QSAR equations have described the forces involved in quantitative terms. The electron characteristic of the substituent at position 4 of the heterocycle and the lipophilic character of the whole molecule were found to significantly affect the antitumour activity in compounds 17-95. Trispyridinium compounds 91-95 are more potent than the bispyridinium ones 87-89 as ChoK inhibitors. Nevertheless, 91-95 are less active than 87-89 as antiproliferative agents because the latter show better lipophilicities to cross the cytosolic membranes. Inhibition of the growth of human tumours in nude mice has been demonstrated: Antitumour activity of compound 64 against human HT-29 produced a decrease of up to 70% in the size of the tumour in nude mice. These results indicate that ChoK can be used as a general target for anticancer drug design against Ras-dependent tumourigenesis.
Export Options
About this article
Cite this article as:
Campos J., Nunez C. M., Conejo-Garcia A., Sanchez-Martin M. R., Hernandez-Alcoceba R., Rodriguez-Gonzalez A., Lacal C. J., Gallo A. M. and Espinosa A., QSAR-Derived Choline Kinase Inhibitors: How Rational can Antiproliferative Drug Design Be?, Current Medicinal Chemistry 2003; 10 (13) . https://dx.doi.org/10.2174/0929867033457539
DOI https://dx.doi.org/10.2174/0929867033457539 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of Cathepsin B
Current Medicinal Chemistry Nanomaterials of Natural Bioactive Compounds for Wound Healing: Novel Drug Delivery Approach
Current Drug Delivery The Effects of Curcumin on Immune Responses
Current Bioactive Compounds Discovery, Structural Determination and Anticancer Activities of Lactucinlike Guaianolides
Letters in Drug Design & Discovery Molecular Docking, Antioxidant, Anticancer and Antileishmanial Effects of Newly Synthesized Quinoline Derivatives
Anti-Cancer Agents in Medicinal Chemistry The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews New and Old Hot Drug Targets in Tuberculosis
Current Medicinal Chemistry Fragment Based HQSAR Modeling and Docking Analysis of Conformationally Rigid 3-azabicyclo [3.1.0] Hexane Derivatives to Design Selective DPP-4 Inhibitors
Letters in Drug Design & Discovery Current Paradigms in COVID-19 Research: Proposed Treatment Strategies, Recent Trends and Future Directions
Current Medicinal Chemistry Fusion Expression and Fibrinolytic Activity of rPA/SP-B
Protein & Peptide Letters Pharmacology of CCKRs and SAR Studies of Peptidic Analog Ligands
Current Topics in Medicinal Chemistry The Prognostic Effect of Clinical and Laboratory Findings on in-hospital Mortality in Patients with Confirmed COVID-19 Disease
Current Respiratory Medicine Reviews Prediction of Nitration Sites Based on FCBF Method and Stacking Ensemble Model
Current Proteomics Carbonic Anhydrase Inhibitors Developed Through ‘Click Tailing’
Current Pharmaceutical Design Extra-Label Use of Ivermectin in Some Minor Ruminant Species: Pharmacokinetic Aspects
Current Pharmaceutical Biotechnology The Genomes of SARS-CoV-2 and Related Coronaviruses: Are Accessory Proteins Key for Pathogenesis?
Coronaviruses Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Carbohydrate Mimics and Lectins: A Source of New Drugs and Therapeutic Opportunities
Mini-Reviews in Medicinal Chemistry Developments in the Synthesis and Biological Activity of Glycyl-LHistydyl- L-Lysine Derivatives
Current Medicinal Chemistry Sepsis Pathophysiology and Anesthetic Consideration
Cardiovascular & Hematological Disorders-Drug Targets